|
WO2021068971A1
|
|
Anti-cd20 antibody formulation and use of anti-cd20 antibody for treatment of cd20 positive diseases
|
|
WO2021043206A1
|
|
Anti-tigit immunosuppressant and application thereof
|
|
WO2020249063A1
|
|
Methods for the treatment of trop2 positive diseases
|
|
CN111982615A
|
|
Dissociation liquid for dissociating drug/ADA compound and application thereof
|
|
CN111973753A
|
|
Anti-tumor combined medicine and application thereof
|
|
WO2020233534A1
|
|
Antibody-drug conjugate preparation, preparation method therefor and use thereof
|
|
CN111808190A
|
|
Antibodies that bind PD-1
|
|
CN110240652A
|
|
Anticomplement D factor antibody and its application
|
|
CN111748580A
|
|
Method for detecting activity of immune checkpoint antibody
|
|
CN110494164A
|
|
A kind of human antibody preparation of targeted therapy TNF-α related disease
|
|
CN110302377A
|
|
A kind of human antibody preparation of targeted therapy TNF-α related disease
|
|
KR20200093628A
|
|
Liquid preparation of humanized antibodies to treat IL-6 related diseases
|
|
CN108918892A
|
|
A kind of active method and its application of measurement anti-VEGF antibody
|
|
CN110003328A
|
|
A kind of the recombination anti-vegf Humanized monoclonal antibodies and its production method of long-acting low toxicity
|
|
CN107446050A
|
|
The compound and method of Trop2 positive diseases treatment
|
|
CN107899020A
|
|
The compound and method of CD20 positive diseases treatment
|
|
CN107881160A
|
|
There are recombinant antibodies of unique sugar spectrum and preparation method thereof caused by a kind of CHO host cells edited as genome
|
|
CN107485713A
|
|
Antibody compositions and its application for TNF α
|
|
CN105079804A
|
|
High-stability humanized antibody preparation for treating VEGF related diseases
|
|
WO2014094355A1
|
|
Compounds and methods for the treatment of egfr positive diseases
|
